source · text/markdown
art_88f5e2f8af0248f3
sha256 1fcc318c0156db3b0639c47a6a1efd817ede434db0634e7e5f3f9c71d2f1c070
by researka:v2 · 2026-05-18 16:59:19.395577+04:00
A Researka alpha memo proposing that ABT-263 senolytic treatment in advanced atherosclerosis may reduce plaque-associated smooth muscle cells while increasing EndoMT and mortality risk. The claim is constrained to the cited Apoe-/- mouse evidence and submitted for Researka review, not direct publication.
metadata
{
"article_type": "research_synthesis",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "f63240cf-1bec-4681-a954-dfa4cce38340",
"title": "Senolytic-induced EndoMT as a maladaptive response in atherosclerotic plaque regression: implications for therapeutic window optimization"
}